Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

The Comparative Value of Hematopoietic Stem Cell Transplantation and Chemotherapy in Cytogenetically Normal AML Subclassified By NPM1 Mutation Status and FLT3 -ITD Allelic Ratio

Blood (2014) 124 (21): 323.

https://doi.org/10.1182/blood.V124.21.323.323

Published: 2014

Journal Articles

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

Edo Vellenga, Wim van Putten, Gert J. Ossenkoppele, Leo F. Verdonck, Matthias Theobald, Jan J. Cornelissen, Peter C. Huijgens, Johan Maertens, Alois Gratwohl, Ron Schaafsma, Urs Schanz, Carlos Graux, Harry C. Schouten, Augustin Ferrant, Mario Bargetzi, Martin F. Fey, Bob Löwenberg, for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), and Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)

Blood (2011) 118 (23): 6037–6042.

https://doi.org/10.1182/blood-2011-07-370247

Published: 2011

Includes: Supplemental data

Journal Articles

Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML

Dietger Niederwieser, MD, Leo F Verdonck, Jan J Cornelissen, MD PhD, Michael Cross, PhD, Rainer Krahl, MD, Thoralf Lange, Vladan Vucinic, Georg Franke, MD, Haifa K. Al-Ali, MD, Gert Ossenkoppele, MD, PhD, Georg Maschmeyer, MD, Gottfried Doelken, MD, Mathias Freund, MD, Norma Peter, Marc Boogaerts, MD, PhD, Alois Gratwohl, MD, Harry C. Schouten, MD, PhD, Bob Lowenberg, MD, PhD

Blood (2011) 118 (21): 2030.

https://doi.org/10.1182/blood.V118.21.2030.2030

Published: 2011

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40–60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning

Blood (2011) 118 (21): 159.

https://doi.org/10.1182/blood.V118.21.159.159

Published: 2011

Journal Articles

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Blood (2010) 115 (13): 2586–2591.

https://doi.org/10.1182/blood-2009-10-246470

Published: 2010

Journal Articles

Poor-Risk Acute Leukemia Patients with An EBMT Low-Risk Score and An 8/8 Matched Unrelated Donor Show Excellent Survival After Hematopoietic Stem Cell Transplantation.

Tom Lodewyck, MD, Machteld Oudshoorn, PhD, Bronno van der Holt, PhD, Eefke Petersen, MD, PhD, Eric Spierings, PhD, Peter A. Von Dem Borne, MD, PhD, Anton Schattenberg, MD, PhD, Wil Allebes, PhD, Ellen Meijer, MD, PhD, Marlies Groenendijk-Sijnke, Lucia Duinhouwer, Roelof Willemze, MD, PhD, Leo F. Verdonck, MD, PhD, Bob Lowenberg, MD, PhD, Jan J. Cornelissen, MD, PhD

Blood (2009) 114 (22): 1196.

https://doi.org/10.1182/blood.V114.22.1196.1196

Published: 2009

Journal Articles

No Direct Effect of NOD2/CARD15 Variants On Clinical Outcome After Non-Myeloablative Allogeneic Stem Cell Transplantation.

Hanneke M. van der Straaten, Martine M. Paquay, Marcel G.J. Tilanus, Leo F. Verdonck, Cynthia Huisman

Blood (2009) 114 (22): 4322.

https://doi.org/10.1182/blood.V114.22.4322.4322

Published: 2009

Journal Articles

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation

Blood (2009) 113 (13): 3110–3118.

https://doi.org/10.1182/blood-2008-07-163212

Published: 2009

Includes: Supplemental data

Journal Articles

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison

Blood (2009) 113 (6): 1375–1382.

https://doi.org/10.1182/blood-2008-07-168625

Published: 2009

Includes: Supplemental data

Journal Articles

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia

Blood (2008) 111 (5): 2581–2588.

https://doi.org/10.1182/blood-2007-08-107482

Published: 2008

Journal Articles

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 + NHL: a prospective randomized HOVON trial

Edo Vellenga, Wim L. J. van Putten, Mars B. van 't Veer, Josée M. Zijlstra, Willem E. Fibbe, Marinus H. J. van Oers, Leo F. Verdonck, Pierre W. Wijermans, Gustaaf W. van Imhoff, Pieternella J. Lugtenburg, Peter C. Huijgens

Blood (2008) 111 (2): 537–543.

https://doi.org/10.1182/blood-2007-08-108415

Published: 2008

Includes: Supplemental data

Journal Articles

Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant.

Blood (2007) 110 (11): 3049.

https://doi.org/10.1182/blood.V110.11.3049.3049

Published: 2007

Journal Articles

Impact of FLT3 Internal Tandem Duplication (FLT3/ITD) on the Outcome of HLA-Identical Sibling Hematopoietic Transplantation for Adult Acute Myeloid Leukemia (AML) in First Remission: Substantial Probability of Leukemia-Free Survival Despite Increased Relapse Risk. A Retrospective Analysis of the EBMT-ALWP.

Salut Brunet, PhD, Myriam Labopin, MD, Jan J. Cornelissen, PhD, Gérard Socié, PhD, Ana Paola Iori, MD, Leo F. Verdonck, PhD, Tapani Ruutu, MD, Alois Gratwohl, MD, Jean-Luc Harousseau, MD, Jorge Sierra, PhD, Vanderson Rocha, PhD

Blood (2007) 110 (11): 1088.

https://doi.org/10.1182/blood.V110.11.1088.1088

Published: 2007

Journal Articles

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myeloid Leukemia Patients Older Than 40 Years.

Cynthia Huisman, MD, PhD, Ellen Meijer, MD, PhD, Eefke J. Petersen, MD, PhD, Henk M. Lokhorst, MD, PhD, Leo F. Verdonck, MD, PhD

Blood (2007) 110 (11): 5074.

https://doi.org/10.1182/blood.V110.11.5074.5074

Published: 2007

Journal Articles

Poor Outcome after Allogeneic Hematopoietic Stem Cell Transplantation for De Novo AML with Chromosome 7 Abnormalities: A Report for the ALWP of the European Group for Blood and Marrow Transplantation.

Agnes Buzyn, MD, PhD, Myriam Labopin, MD, Jurgen Finke, MD, Tapani Ruutu, MD, G. Ehninger, MD, Leo F. Verdonck, MD, Gerard Socie, MD, PhD, Roelof Willemze, MD, Karel Indrak, MD, Nigel H. Russell, MD, Vanderson Rocha, for the ALWP of the EBMT

Blood (2007) 110 (11): 325.

https://doi.org/10.1182/blood.V110.11.325.325

Published: 2007

Journal Articles

The In Vivo Impact of Human Regulatory T Cells on the Graft Versus Tumor Effect.

Tuna Mutis, MD, PhD, Henk Rozemuller, PhD, Maarten E. Emmelot, Tineke Aarts-Riemens, Vivienne Verweij, Saskia Ebeling, PhD, Leo F. Verdonck, MD, PhD, Henk Lockhorst, MD, PhD, Anton Martens, PhD

Blood (2007) 110 (11): 349.

https://doi.org/10.1182/blood.V110.11.349.349

Published: 2007

Journal Articles

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

Jan J. Cornelissen, Wim L. J. van Putten, Leo F. Verdonck, Matthias Theobald, Emanuel Jacky, Simon M. G. Daenen, Marinus van Marwijk Kooy, Pierre Wijermans, Harry Schouten, Peter C. Huijgens, Hans van der Lelie, Martin Fey, Augustin Ferrant, Johan Maertens, Alois Gratwohl, Bob Lowenberg

Blood (2007) 109 (9): 3658–3666.

https://doi.org/10.1182/blood-2006-06-025627

Published: 2007

Includes: Supplemental data

Journal Articles

Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)

Leo F. Verdonck, Annelise Notenboom, Daphne D. de Jong, Marius A. MacKenzie, Gregor E. G. Verhoef, Mark H. H. Kramer, Gert J. Ossenkoppele, Jeanette K. Doorduijn, Pieter Sonneveld, Gustaaf W. van Imhoff

Blood (2006) 109 (7): 2759–2766.

https://doi.org/10.1182/blood-2006-07-035709

Published: 2006

Includes: Supplemental data

Journal Articles

Allogeneic SCT with Matched Related and Unrelated Donors for Patients (pts) with Refractory Anemia (RA): Improved Survival after Introduction of Reduced Intensity Conditioning (RIC) Regimens.

T.M. de Witte, MD, Ronald Brand, PhD, Anja van Biezen, Ghulam Mufti, MD, Tapani Ruutu, MD, Jurgen Finke, MD, Peter von dem Borne, MD, Antonin Vitek, MD, Michel Delforge, MD, Paolo E. Alessandrino, MD, Nicholas Harhalakis, MD, Nigel H. Russell, MD, Enric Carreras, MD, Leo F. Verdonck, MD, Dietger W. Niederwieser, MD

Blood (2006) 108 (11): 519.

https://doi.org/10.1182/blood.V108.11.519.519

Published: 2006

Journal Articles

Impact of Cytogenetics on Outcome of Patients with MDS or Secondary AML Undergoing Allogeneic HSCT from HLA-Identical Siblings: A Retrospective Analysis of the EBMT-CLWP.

Francesco Onida, MD, Ronald Brand, PhD, Anja van Biezen, Renee M. Barge, MD, Leo F. Verdonck, MD, Jurgen Finke, MD, Dietrich Beelen, MD, Rodrigo Martino, MD, José M. Fernandez-Ranada, MD, Dietger Niederwieser, MD, Nicolaus Kröger, MD, Theo de Witte, MD

Blood (2006) 108 (11): 2653.

https://doi.org/10.1182/blood.V108.11.2653.2653

Published: 2006

NARROW

The Comparative Value of Hematopoietic Stem Cell Transplantation and Chemotherapy in Cytogenetically Normal AML Subclassified By NPM1 Mutation Status and FLT3 -ITD Allelic Ratio

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML

Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40–60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Poor-Risk Acute Leukemia Patients with An EBMT Low-Risk Score and An 8/8 Matched Unrelated Donor Show Excellent Survival After Hematopoietic Stem Cell Transplantation.

No Direct Effect of NOD2/CARD15 Variants On Clinical Outcome After Non-Myeloablative Allogeneic Stem Cell Transplantation.

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 + NHL: a prospective randomized HOVON trial

Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myeloid Leukemia Patients Older Than 40 Years.

Poor Outcome after Allogeneic Hematopoietic Stem Cell Transplantation for De Novo AML with Chromosome 7 Abnormalities: A Report for the ALWP of the European Group for Blood and Marrow Transplantation.

The In Vivo Impact of Human Regulatory T Cells on the Graft Versus Tumor Effect.

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)

Allogeneic SCT with Matched Related and Unrelated Donors for Patients (pts) with Refractory Anemia (RA): Improved Survival after Introduction of Reduced Intensity Conditioning (RIC) Regimens.

Impact of Cytogenetics on Outcome of Patients with MDS or Secondary AML Undergoing Allogeneic HSCT from HLA-Identical Siblings: A Retrospective Analysis of the EBMT-CLWP.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only